Antitumor Activity of Bortezomib Alone and in Combination with Trail in Human Acute Myeloid Leukemia

Publisher： Karger

E-ISSN： 1421-9662|120|1|19-30

ISSN： 0001-5792

Source： Acta Haematologica, Vol.120, Iss.1, 2008-08, pp. : 19-30

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Immunotherapy in acute myeloid leukemia

By  

CANCER, Vol. 121, Iss. 16, 2015-08 ,pp. : 2689-2704

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 401-407

John Wiley & Sons Inc

Access to resources Recommend Favorite

Genetic Variation in Human Leukocyte Antigen and Susceptibility to Acute Myeloid Leukemia

By  

Acta Haematologica, Vol. 133, Iss. 2, 2014-09 ,pp. : 162-163

Karger

Access to resources Recommend Favorite

Recent Advancements of Bortezomib in Acute Lymphocytic Leukemia Treatment

By  

Acta Haematologica, Vol. 129, Iss. 4, 2013-01 ,pp. : 207-214

Karger

Access to resources Recommend Favorite

Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer

By  

Case Reports in Oncology, Vol. 7, Iss. 2, 2014-05 ,pp. : 316-322

Karger

Access to resources Recommend Favorite